Important study that evaluates timely access to therapeutics across Englands Integrated Care Boards (ICBs)

Final Kintiga – Pfizer -COVID-19 Report – FINAL-1

This report evaluates the timely access to therapeutics for individuals at the highest risk of becoming seriously ill with COVID-19 across England’s Integrated Care Boards (ICBs). It highlights significant challenges in equitable access, public awareness and service delivery following the transition of national policy to a “living with COVID-19” approach. This report is the first in a two-part series. The second report will be informed by stakeholder perspectives on the key findings of this report, focusing on the challenges and opportunities with timely access to COVID-19 therapeutics and it will also examine the potential impact of reforms to NHS England.

Evidence from the UK COVID-19 Inquiry underscores that individuals with the highest risk of becoming seriously ill with COVID-19 have struggled to access timely treatment, which is critical given the narrow five-day treatment window of antivirals.